Research Insights

Rethinking Beta-blockers Post-Heart Attack

As a Cardiologist, my primary commitment is to equip my patients with the latest evidence-based insights crucial for optimal cardiovascular health. Our consultations meticulously evaluate numerous research findings to determine the most effective medications for managing heart conditions. Various therapeutic approaches offer substantial benefits, ultimately improving patient outcomes and quality of life.

Following a heart attack, a critical phase of your treatment often involves hospitalization and the initiation of multiple medications to support your recovery. Beta-blockers have traditionally played a significant role in this regimen, owing to their historical effectiveness in promoting cardiac wellness. However, recent data has sparked intriguing discussions regarding the necessity of beta blockers for patients with preserved heart function post-heart attack.

This article delves into the evolving understanding of beta-blocker usage after heart attacks, particularly for individuals with maintained heart function. We will explore the latest insights from the medical field to develop a more nuanced perspective on the role of beta blockers in contemporary cardiac care strategies.


Redefining Beta Blockers: A Closer Look Post-Heart Attack

Beta-blockers have traditionally been central to treatment protocols, often prescribed alongside other medications following a heart attack (myocardial infarction). These medications, recognized for their potential across various conditions, have lately been under scrutiny in light of a recent study in a select group of patients whose heart function is normal.

Understanding the concept of left ventricular (LV) ejection fraction, which indicates whether the heart is contracting normally, is crucial. This measure helps assess the risk level. Beta-blocker effects may depend on whether the LV ejection fraction is maintained or reduced. Clinical studies involving patients with heart failure and a decreased LV ejection fraction provide strong evidence that beta-blockers can significantly reduce the risk of long-term heart failure-related hospitalizations and cardiovascular mortality. This evidence supports the continued use of beta-blockers due to their beneficial impact on prognosis.

Explore the concept of normal heart function and gain insight into the term “ejection fraction” through our informative YouTube video.


Rethinking Beta-blockers Post-Heart Attack Heart Matters



It should be noted that this present study (SWEDEHEART) excluded patients whose heart function was reduced and therefore beta blockers remain the backbone of improving well-being, heart function, and quality of life in this patient population.


Beta-blockers commonly used in patients whose heart function is reduced

  1. Carvedilol
    • Generic Name: Carvedilol
    • Trade Names: Coreg, Dilatrend
  2. Bisoprolol
    • Generic Name: Bisoprolol
    • Trade Names: Zebeta, Concor, Emcor, Bicor
  3. Nebivolol
    • Generic Name: Nebivolol
    • Trade Names: Bystolic, Nebilet
  4. Metoprolol Succinate (Extended-Release)
    • Generic Name: Metoprolol Succinate
    • Trade Names: Toprol XL, Betaloc CR, Seloken XL


It should be noted that this present study (SWEDEHEART) excluded patients whose heart function was reduced. Therefore, the above class of beta blockers remains the backbone of improving well-being, heart function, and quality of life. If you are currently prescribed beta blockers for heart failure with reduced ejection fraction, it’s essential to continue taking your medication as directed by your healthcare provider. Discontinuing medications abruptly can have adverse effects and impact your overall health. Always consult your healthcare provider before making any changes to your medication regimen.


Rethinking Beta-blockers Post-Heart Attack Heart Matters


Unveiling New Perspectives: The SWEDEHEART Registry Study

The SWEDEHEART registry study has emerged as an interesting exploration that challenges the convention surrounding prolonged beta-blocker usage in those with normal heart function following a heart attack. The SWEDEHEART registry study examined 43,618 patients who had experienced a previous heart attack (myocardial infarction) and did not exhibit heart failure or left ventricular systolic dysfunction.

The study found no association between long-term beta-blocker use and mortality or significant cardiovascular events in this patient population.

Analyzing the Study Findings

Over a median follow-up period of 4.5 years, the study found no significant difference in the risk of a combined outcome involving all-cause mortality, recurrent myocardial infarction (MI), unscheduled revascularization procedures, or hospitalization for heart failure. This comparison was drawn between patients who were and weren’t utilizing beta-blockers one year after their myocardial infarction (MI), as outlined by the study’s lead author, Dr. Divan Ishak of Uppsala University, Sweden, and his colleagues. The study’s results were published online in the journal Heart.

While the study encompassed an extensive patient cohort exceeding 40,000 individuals, it’s important to acknowledge the inherent limitations of an observational approach. Unlike randomized clinical trials, this study design presents certain constraints. Examining the two groups more closely, differences emerged between the approximately 78% of patients using beta-blockers and the remaining 22%. The beta-blocker group demonstrated a lower likelihood of prior myocardial infarction, cerebral or peripheral vascular disease, or previous coronary revascularization. Conversely, they were more inclined to undergo revascularization during their index myocardial infarction hospitalization and to receive prescriptions for aspirin, ACE inhibitors, and statins.

Nonetheless, the study offers valuable insights for contemplation, igniting anticipation for ongoing and upcoming randomized trials poised to generate even more substantial excitement in the future.


Modern Context: Evolution of Heart Attack Treatments

The context of heart attack treatment has evolved significantly over time. The landscape has shifted with the advent of contemporary interventions such as percutaneous coronary intervention (PCI) with stenting alongside a comprehensive medication regimen. These combined strategies have remarkably minimized the likelihood of post-heart attack complications, including heart failure.


Beta-Blockers’ Evolving Role: Insights from Ongoing Trials

The medical community continues to be captivated by the question of beta-blocker utility. Various studies have attempted to gauge their supplementary advantages when combined with existing heart attack treatments, leading to a mosaic of findings. A series of ongoing trials aim to provide more conclusive evidence in this complex narrative.

  • The ABYSS trial, a nationwide multicenter study, dissects the ramifications of interrupting beta-blocker therapy after an uncomplicated myocardial infarction (MI) versus continuous therapy, with major cardiovascular events as the primary endpoint.
  • The BETAMI trial, on the other hand, is directed towards gauging the superiority of oral beta-blocker therapy over no-treatment post-acute myocardial infarction (AMI), focusing on enhancing post-AMI outcomes.
  • The REBOOT clinical trial delves into whether sustained beta-blocker therapy positively impacts individuals who’ve experienced heart attacks without reduced left ventricular function.

Empowering Informed Decisions: Balancing Risks and Benefits

These ongoing trials carry the potential to reshape our evidence-based guidelines and evolve personalized treatment strategies. It’s essential to underscore that these findings should not prompt individuals to halt beta-blocker usage without consulting healthcare professionals. Instead, they emphasize the value of open dialogues between patients and healthcare providers. As healthcare professionals, we are pivotal in helping patients make informed choices, evaluating their circumstances, and considering the latest available evidence.


In conclusion, I view this as an intriguing juncture to monitor closely. As a clinician, I consistently assess medication indications with my patients, recognizing that while beta-blockers hold potential benefits, they also have potential side effects. These may involve fatigue, mood fluctuations, concerns about erectile function, aggravated asthma symptoms, and occasional low blood pressure.

Striking a delicate balance between potential advantages and individual patient experiences, I am dedicated to guiding my patients toward informed choices that prioritize their health and well-being. Moreover, I may prioritize other classes of medications, such as ACE inhibitors or Angiotensin receptor blockers, over beta blockers for controlling factors like blood pressure. It is imperative, however, to engage in open discussions with your healthcare professional to seek independent advice tailored to your specific circumstances.


Ishak DAktaa SLindhagen L, et al
Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes. Link to Study



Search articles


Subscribe for exclusive heart health resources, valuable tips, and the latest research updates.

Editor's Picks

Empowering heart health

Subscribe to our newsletter and be the first to receive valuable insights, tips, and resources on heart health.

other anti-anginals

When first-line therapies for angina, such as beta blockers, calcium channel blockers, and nitrates, prove inadequate or are not well-tolerated, second-line therapies may be considered.
Perhexiline is a unique medication that enhances the heart's ability to utilize fatty acids for energy, reducing its reliance on oxygen and lowering oxygen demand. This action helps improve blood flow and alleviates chest pain in some patients with refractory angina.
Nicorandil is another second-line option with a dual mechanism of action. It opens potassium channels in smooth muscle cells, causing vasodilation and enhancing coronary blood flow. Additionally, nicorandil also stimulates nitric oxide release, further dilating blood vessels and reducing heart workload.
Trimetazidine is an anti-ischemic agent that improves cardiac efficiency by enhancing glucose metabolism and shifting the heart's energy production to a more oxygen-efficient process. As second-line therapies, these medications offer alternative approaches for managing angina in individuals who do not respond adequately to first-line treatments or those experiencing side effects from other medications.

lipid lowering therapies

Lipid-lowering therapies play a critical role in managing coronary artery disease (CAD), a condition characterized by the narrowing of blood vessels that supply the heart. Among the most commonly discussed and debated classes of medications are statins, which effectively reduce cholesterol levels and are widely prescribed to lower the risk of cardiovascular events. Alongside statins, other medications like ezetimibe, fibrates, and niacin are also utilized to target specific aspects of lipid metabolism, such as cholesterol absorption, triglyceride levels, and raising high-density lipoprotein (HDL) cholesterol. Additionally, the introduction of medications that inhibit PCSK9, an enzyme involved in cholesterol metabolism, has provided a promising new approach to further lower LDL cholesterol levels. These PCSK9 inhibitors, such as Repatha (evolocumab), have shown significant efficacy in reducing LDL cholesterol levels in patients with CAD, especially for those who may not respond well to traditional therapies.


Nitrates are widely used to treat angina and provide quick relief for chest pain. Commonly available in the form of sublingual sprays or tablets, patches, and long-acting tablets, nitrates work by dilating blood vessels, allowing for increased blood flow and reduced resistance. This dilation eases the heart's workload, leading to a decreased demand for oxygen and prompt alleviation of angina symptoms. Sublingual nitrates act rapidly and are often used to provide immediate relief during angina attacks, while patches and long-acting tablets are employed for preventive purposes. However, nitrates may cause side effects such as headaches, dizziness, and flushing, which usually subside over time.

calcium channel blockers

Calcium channel blockers, including amlodipine, felodipine, cardizem (diltiazem), and verapamil, are commonly prescribed for the treatment of angina. These medications work by inhibiting the influx of calcium into the muscle cells of the heart and blood vessels, leading to their relaxation. As a result, blood vessels widen, promoting improved blood flow and reduced blood pressure. In the context of angina, this relaxation decreases the heart's workload, lowering the demand for oxygen and alleviating chest pain. Calcium channel blockers offer a valuable treatment option for individuals with angina, but it is essential to be aware of potential side effects, which may include headaches, dizziness, flushing, and ankle swelling.

Beta blockers

Beta blockers, such as metoprolol, propranolol, atenolol, carvedilol, and bisoprolol, play a crucial role in treating angina. By blocking certain receptors in the heart, they effectively reduce heart rate and the force of contraction, thereby easing the heart's workload. This mechanism of action leads to a decreased demand for oxygen, making beta blockers highly effective in relieving chest pain associated with angina. As with any medication, it's important to consider potential side effects, including tiredness, worsened asthma, erectile dysfunction in some males, and more vivid dreams during sleep. Consult your healthcare provider to determine the suitability of beta blockers for managing your angina and overall heart health.

Anti-platelet Medications

Anti-platelet medications play a crucial role in preventing blood clot formation, reducing the risk of serious cardiovascular events such as heart attacks and strokes. Among the widely used anti-platelet drugs are aspirin, clopidogrel, and ticagrelor.

Aspirin: This well-known medication inhibits platelet activation, making it less likely for platelets to stick together and form clots. Aspirin is commonly used for primary and secondary prevention of heart attacks and strokes.

Clopidogrel: As a potent anti-platelet agent, clopidogrel works by blocking specific receptors on platelets, preventing them from aggregating. It is often prescribed to patients with acute coronary syndrome, those undergoing stent procedures, and for some cases of peripheral arterial disease.

Ticagrelor: Ticagrelor is another effective anti-platelet drug that works by inhibiting platelet activation. It is used in acute coronary syndrome, often given alongside aspirin to reduce the risk of heart-related events.